论文部分内容阅读
目的评价普罗布考预防经皮冠状动脉介入治疗(PCI)后再狭窄的作用。方法将准备行PCI的82例稳定型心绞痛患者随机分为普罗布考组(n=42)和普伐他汀组(n=40)。两组患者于术前4周开始服用普罗布考1 000 mg/d或普伐他汀40 mg/d。服药4周后行金属裸支架置入术。术后继续原剂量及方法服用药物至24周。出院后定期随访,术后24周复查冠状动脉造影。结果PCI后随访至24周,两组严重临床事件发生率(死亡、急性心肌梗死、卒中及紧急血运重建术)差异无统计学意义(P>0.05)。复查冠状动脉造影结果显示普罗布考组再狭窄率(22.5%)低于普伐他汀组(36.8%,P<0.05),普罗布考组管腔直径狭窄率及晚期管腔丢失指数(分别为23.25%±10.08%及0.25±0.41)均低于普伐他汀组(分别为34.76%±16.99%及0.42±0.68,P<0.05),纯获得(2.11±1.02 mm)大于普伐他汀组(1.51±0.96 mm,P<0.05)。而两组晚期管腔丢失比较则差异无统计学意义(P>0.05)。结论PCI前4周应用普罗布考降低PCI后再狭窄率的作用优于普伐他汀。
Objective To evaluate the role of probucol in preventing restenosis after percutaneous coronary intervention (PCI). Methods 82 patients with stable angina who underwent PCI were randomly divided into probucol group (n = 42) and pravastatin group (n = 40). Both groups started taking probucol 1 000 mg / day or pravastatin 40 mg / d 4 weeks prior to surgery. Four weeks after taking the bare metal stent implantation. Continue after the original dose and method of medication to 24 weeks. Regular follow-up after discharge, coronary angiography after 24 weeks review. Results There was no significant difference in the incidence of serious clinical events (death, acute myocardial infarction, stroke and emergency revascularization) between the two groups (P> 0.05) after PCI was followed up for 24 weeks. The results of coronary angiography showed that the restenosis rate in probucol group was lower than that in pravastatin group (36.8%, P <0.05), and the stenosis rate and late luminal loss index in probucol group were 23.25% ± 10.08% and 0.25 ± 0.41) were lower than those in pravastatin group (34.76% ± 16.99% and 0.42 ± 0.68 respectively, P <0.05) ± 0.96 mm, P <0.05). There was no significant difference in the loss of late luminal between the two groups (P> 0.05). Conclusions The effect of reducing the rate of restenosis after PCI with probucol 4 weeks before PCI is better than pravastatin.